104 related articles for article (PubMed ID: 9731502)
61. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96.
Janetzki S; Blachere NE; Srivastava PK
J Immunother; 1998 Jul; 21(4):269-76. PubMed ID: 9672848
[TBL] [Abstract][Full Text] [Related]
62. Escape from immune surveillance does not result in tolerance to tumor-associated antigens.
Melchionda F; McKirdy MK; Medeiros F; Fry TJ; Mackall CL
J Immunother; 2004; 27(5):329-38. PubMed ID: 15314541
[TBL] [Abstract][Full Text] [Related]
63. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.
de Witte MA; Bendle GM; van den Boom MD; Coccoris M; Schell TD; Tevethia SS; van Tinteren H; Mesman EM; Song JY; Schumacher TN
J Immunol; 2008 Aug; 181(4):2563-71. PubMed ID: 18684947
[TBL] [Abstract][Full Text] [Related]
64. The 2C T-cell transgenic mouse: an in vivo model of allospecific cytotoxic T-cell activation and homing.
Stegall MD; Elices M; Shepard G; Gup C; Ninova D; Ferguson D; Gill RG
Transplant Proc; 1999; 31(1-2):779. PubMed ID: 10083330
[No Abstract] [Full Text] [Related]
65. Optimization of TCR transgenic T cells for in vivo tracking of immune responses.
Stock AT; Mueller SN; Kleinert LM; Heath WR; Carbone FR; Jones CM
Immunol Cell Biol; 2007 Jul; 85(5):394-6. PubMed ID: 17549072
[TBL] [Abstract][Full Text] [Related]
66. An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.
Hasegawa K; Tanaka S; Fujiki F; Morimoto S; Nakajima H; Tatsumi N; Nakata J; Takashima S; Nishida S; Tsuboi A; Oka Y; Oji Y; Kumanogoh A; Sugiyama H; Hosen N
PLoS One; 2015; 10(12):e0144594. PubMed ID: 26658107
[TBL] [Abstract][Full Text] [Related]
67. Real-time analysis of T cell receptors in naive cells in vitro and in vivo reveals flexibility in synapse and signaling dynamics.
Friedman RS; Beemiller P; Sorensen CM; Jacobelli J; Krummel MF
J Exp Med; 2010 Nov; 207(12):2733-49. PubMed ID: 21041455
[TBL] [Abstract][Full Text] [Related]
68. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
Willimsky G; Czéh M; Loddenkemper C; Gellermann J; Schmidt K; Wust P; Stein H; Blankenstein T
J Exp Med; 2008 Jul; 205(7):1687-700. PubMed ID: 18573907
[TBL] [Abstract][Full Text] [Related]
69. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.
Kitchen SG; Bennett M; Galić Z; Kim J; Xu Q; Young A; Lieberman A; Joseph A; Goldstein H; Ng H; Yang O; Zack JA
PLoS One; 2009 Dec; 4(12):e8208. PubMed ID: 19997617
[TBL] [Abstract][Full Text] [Related]
70. TCR Gene Therapy for Cancer.
Rhein S; Çakmak-Görür N
Methods Mol Biol; 2022; 2521():95-128. PubMed ID: 35732995
[TBL] [Abstract][Full Text] [Related]
71. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.
Kunert A; Chmielewski M; Wijers R; Berrevoets C; Abken H; Debets R
Oncoimmunology; 2017; 7(1):e1378842. PubMed ID: 29296541
[TBL] [Abstract][Full Text] [Related]
72. Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma
Kirschner A; Thiede M; Grünewald TG; Alba Rubio R; Richter GH; Kirchner T; Busch DH; Burdach S; Thiel U
Oncoimmunology; 2017; 6(2):e1273301. PubMed ID: 28344885
[TBL] [Abstract][Full Text] [Related]
73. Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.
Nowicki TS; Peters CW; Quiros C; Kidd CK; Kawakami M; Klomhaus AM; Baselga-Carretero I; Kaplan-Lefko P; Macabali MH; Perez Garcilazo I; Berent-Maoz B; Comin-Anduix B; Ribas A
Cancer Immunol Res; 2023 Dec; 11(12):1589-1597. PubMed ID: 37871333
[TBL] [Abstract][Full Text] [Related]
74. Machine learning predictions of T cell antigen specificity from intracellular calcium dynamics.
This S; Costantino S; Melichar HJ
Sci Adv; 2024 Mar; 10(10):eadk2298. PubMed ID: 38446885
[TBL] [Abstract][Full Text] [Related]
75. Transgenic Animals within the 3R concept.
Gruber FP
ALTEX; 1998; 15(1):26-28. PubMed ID: 11208265
[TBL] [Abstract][Full Text] [Related]
76. Tumour neoantigen mimicry by microbial species in cancer immunotherapy.
Boesch M; Baty F; Rothschild SI; Tamm M; Joerger M; Früh M; Brutsche MH
Br J Cancer; 2021 Aug; 125(3):313-323. PubMed ID: 33824481
[TBL] [Abstract][Full Text] [Related]
77. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.
Hargadon KM; Bishop JD; Brandt JP; Hand ZC; Ararso YT; Forrest OA
Immunol Cell Biol; 2016 Jan; 94(1):24-38. PubMed ID: 26010746
[TBL] [Abstract][Full Text] [Related]
78. Control of the immune response by pro-angiogenic factors.
Voron T; Marcheteau E; Pernot S; Colussi O; Tartour E; Taieb J; Terme M
Front Oncol; 2014; 4():70. PubMed ID: 24765614
[TBL] [Abstract][Full Text] [Related]
79. Dendritic cell-specific delivery of Flt3L by coronavirus vectors secures induction of therapeutic antitumor immunity.
Perez-Shibayama C; Gil-Cruz C; Nussbacher M; Allgäuer E; Cervantes-Barragan L; Züst R; Ludewig B
PLoS One; 2013; 8(11):e81442. PubMed ID: 24312302
[TBL] [Abstract][Full Text] [Related]
80. Tumor-altered dendritic cell function: implications for anti-tumor immunity.
Hargadon KM
Front Immunol; 2013; 4():192. PubMed ID: 23874338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
